Xu Jian, Du Wei
Division of Hematology and Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Philadelphia, USA.
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
J Clin Invest. 2025 Apr 1;135(7):e191355. doi: 10.1172/JCI191355.
Nucleoporin 98 (NUP98) fusion oncogenes are known to promote aggressive pediatric leukemia by disrupting chromatin structure and modulating the expression of homeobox (HOX) genes, yet the precise molecular events are unclear. In this issue of the JCI, K. Hamamoto et al. explore the mechanistic underpinnings of NUP98 fusion-driven pediatric leukemia, with a focus on aberrant activation of the Hoxb-associated long, noncoding RNA (lncRNA) HoxBlinc. The authors provide compelling evidence that HoxBlinc plays a central role in the oncogenic transformation associated with NUP98 fusion protein. The study underscores a CTCF-independent role of HoxBlinc in the regulation of topologically associated domains (TADs) and chromatin accessibility, which has not been fully appreciated in previous research on the NUP98 fusion oncogenes. The discovery of HoxBlinc lncRNA as a downstream regulator of NUP98 fusion oncoproteins offers a potential target for therapeutic intervention in pediatric leukemia.
已知核孔蛋白98(NUP98)融合致癌基因通过破坏染色质结构和调节同源盒(HOX)基因的表达来促进侵袭性小儿白血病,但其确切的分子事件尚不清楚。在本期《临床研究杂志》中,K. 滨本等人探讨了NUP98融合驱动的小儿白血病的机制基础,重点关注与Hoxb相关的长链非编码RNA(lncRNA)HoxBlinc的异常激活。作者提供了令人信服的证据,表明HoxBlinc在与NUP98融合蛋白相关的致癌转化中起核心作用。该研究强调了HoxBlinc在拓扑相关结构域(TADs)调控和染色质可及性方面不依赖CTCF的作用,这在先前关于NUP98融合致癌基因的研究中尚未得到充分认识。HoxBlinc lncRNA作为NUP98融合癌蛋白的下游调节因子的发现为小儿白血病的治疗干预提供了一个潜在靶点。